The Gender Divide

The most reliable thing the 2026 data says about gender is that men and women in the same companies, the same age bands, the same metros, do not fail the same markers. They fail different ones. Female anemia runs at 34.6% against a male rate of 8.9% — a 3.9× gap, the widest single-marker gender difference anywhere in this report. Male liver elevation runs at 27.5% against a female rate of 7.8% — a 3.5× gap in the other direction. Indian national data has documented the female anemia burden for years; NFHS-5 put anemia among adult women at 57% nationally (IIPS & ICF, National Family Health Survey-5, 2021). What the Loop data adds is the other half of the picture: in a single insured workforce, the men are not healthier than the women. They are unhealthy along a different axis.

This page pulls the gender signal from across the report — glucose, anemia, liver, uric acid, lipids, sleep, stress, substance use, and claims — and reads them together. The story is not "who is worse off." It is that two physiologies, two coping patterns, and two screening blind spots sit inside the same group policy, and a wellness programme calibrated to the average serves neither.

Men and women fail different markers, not the same one harder#

The headline biomarker table is best read as two columns that don't rhyme.

Anemia and liver sit at opposite poles. Between them, glucose dysfunction is the one marker where the two genders converge — 39.9% of women, 37.6% of men, close enough that the population-average "no gender gap on glucose" reading is correct on its face. It is also, as the age cut below shows, wrong in its details. The triglyceride and uric-acid gaps point male; the anemia gap points hard female. The reason the two columns don't rhyme is that they are driven by different things — iron loss and reproductive physiology on one side, substance load and visceral fat on the other.

Anemia is the largest gender gap in the report — and Mumbai is its epicentre#

One in three women in this workforce is anemic. The clinical floor for the finding is not subtle: iron deficiency at this prevalence degrades attention, working memory, and exercise tolerance across the most productive years of a career, and it sits almost entirely undetected because a haemoglobin reading requires a blood draw that three-quarters of the workforce don't get in a given year.

The city cut is where the finding sharpens.

The gap between Mumbai (52.3%) and Bengaluru (23.2%) is 29 points — more than twice the size of the national male-female anemia gap. Half the women tested in Mumbai are anemic. This is not an isolated marker, either: Mumbai women also lead on glucose dysfunction (49.8%) and on low HDL (78.1%). On the three markers that matter most for women's biomarker health, Mumbai is the worst metro in the dataset on all three.

The cross-year movement is mild and in the right direction: female anemia fell from 37.1% in WHI 2025 to 34.6% in 2026, on a far larger sample. The thresholds match exactly across years. It is the cleanest year-on-year gender signal in the report, and it has barely moved — which is itself the finding. A workforce running at one-in-three anemic women in two consecutive editions is running at a structural rate, not a noisy one.

The male profile is a substance-coping profile#

The markers that skew male — liver enzymes, uric acid, triglycerides — are the markers most directly downstream of alcohol, tobacco, and the visceral fat that comes with them. The survey-side behaviour lines up.

Weekly alcohol use is 3.4× more common in men; nicotine use 3.0×. The biomarker consequence is visible one table up: male liver elevation at 27.5% (3.5× the female rate) and male hyperuricaemia at 24.3% (2.1×). The survey behaviour and the blood chemistry are describing the same population from two angles. Men drink and smoke more, and their livers and urate levels register it.

The therapy and exercise rows run the other way, and they matter. Women are twice as likely to have ever taken therapy (15.7% vs 7.8%) and more likely to report no exercise at all (38.2% vs 27.5%). Men move more and talk to professionals less. The substance load, on this reading, is partly a coping channel — the stress that women route into therapy and men route, disproportionately, into alcohol and tobacco.

Men's metabolic markers peak in the 30s; women's climb past 50#

The single most important cut on this page is what happens to the gender gap across age. Read at the population average, several markers look roughly even between men and women. Split by age band, they invert.

Diabetic-range glucose (HbA1c ≥6.5%), by gender and age:

In the 30s, men are 2.4× more likely than women to be in the diabetic glucose range. By 60, the two lines have met. The male disadvantage is a mid-career phenomenon — concentrated exactly in the decade when most operating responsibility lands — and it dissolves as women's rates catch up later in life. The Blood Sugar page tracks this mid-career male glucose disadvantage in full, against the population-average curve it hides inside.

Hyperuricaemia draws the same shape, more dramatically, and it crosses over:

In their 20s and 30s, men's hyperuricaemia rate is roughly 3× the women's. Then the male line falls — from 28.0% in the 30s to 12.1% in the 50s — while the female line climbs steadily, from 7.3% in the 20s to 29.5% by 60. The two lines cross in the late 40s. By 60, women's urate burden exceeds men's. The Kidney page reads the same uric-acid flip from the renal side, where the oestrogen-withdrawal mechanism becomes a kidney-stone and gout signal. The same crossover sits, fainter, behind the glucose and lipid data — the Lipids page shows oestrogen's HDL protection eroding on the same post-menopausal clock. It has a single mechanism.

Women carry the stress and sleep deficit, and the gap is widening#

The survey side of the divide is sharpest on stress, and it is the most reproducible gender finding in the report across editions.

Nearly half of women in this workforce report high stress, against just over a third of men. Women are also a third more likely to sleep under six hours. The two reinforce each other — short sleep raises next-day stress reactivity, and elevated stress delays sleep onset — and the female figures sit at the bad end of both.

The cross-year movement is the concerning part. Female high stress rose from 41.2% in WHI 2025 to 47.4% in 2026 — a 6.2-point increase, the largest year-on-year move on any gender measure in either direction. The male rate moved far less. Whatever is driving the stress gap, it widened over the year, not narrowed.

In the claims data, women cost slightly less per claim — and maternity is a fifth of their total#

The claims file records claimant gender, which lets the divide be read on spend as well as on biology. The shares are close; the composition is not.

Women file more claims than men (48.2% vs 44.8%) but account for fewer rupees (45.7% vs 47.3%), because the male claim costs more on average — ₹45,535 against ₹40,848, an 11% premium. The female claim share runs ahead of the female share of the employee base because the spouse layer on these policies is overwhelmingly female, and that layer brings the largest single female claim line with it.

Maternity is the defining female claim line. Across the book, maternity accounts for roughly 21% of all female claims and 21.7% of all female incurred cost — about ₹34.6 Cr in the window. Strip maternity out, and the female claim profile converges toward the male one. A generation up, the same biological divide reappears on the parent layer as the mother's bones and the father's heart — the Parent Claims page shows post-menopausal fracture cost landing on mothers and cardiac cost on fathers. The single largest driver of female healthcare spend in this workforce is not a disease. It is childbirth, concentrated in the late 20s and 30s, in the same band where the female biomarker profile is at its healthiest relative to men's.

The divide isn't a ranking#